CPHI Stock Overview
China Pharma Holdings, Inc. develops, manufactures, and markets generic and branded pharmaceutical, and biochemical products primarily to hospitals and private retailers in the People’s Republic of China.
China Pharma Holdings Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$0.14|
|52 Week High||US$0.79|
|52 Week Low||US$0.13|
|1 Month Change||-24.16%|
|3 Month Change||-36.77%|
|1 Year Change||-72.66%|
|3 Year Change||-44.40%|
|5 Year Change||-19.91%|
|Change since IPO||-99.57%|
Recent News & Updates
|CPHI||US Pharmaceuticals||US Market|
Return vs Industry: CPHI underperformed the US Pharmaceuticals industry which returned 3.2% over the past year.
Return vs Market: CPHI underperformed the US Market which returned -23.2% over the past year.
|CPHI Average Weekly Movement||9.6%|
|Pharmaceuticals Industry Average Movement||11.2%|
|Market Average Movement||6.8%|
|10% most volatile stocks in US Market||15.5%|
|10% least volatile stocks in US Market||2.8%|
Stable Share Price: CPHI is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week.
Volatility Over Time: CPHI's weekly volatility (10%) has been stable over the past year.
About the Company
China Pharma Holdings, Inc. develops, manufactures, and markets generic and branded pharmaceutical, and biochemical products primarily to hospitals and private retailers in the People’s Republic of China. The company offers products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. Its products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain; Propylgallate and Ozagrel Sodium to treat cerebral thrombosis, coronary heart disease, and after surgery complications; Alginic Sodium Diester injection for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Bumetanide injection to treat edema diseases; and Candesartan for hypertension.
China Pharma Holdings Fundamentals Summary
|CPHI fundamental statistics|
Is CPHI overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|CPHI income statement (TTM)|
|Cost of Revenue||US$8.48m|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.074|
|Net Profit Margin||-46.08%|
How did CPHI perform over the long term?See historical performance and comparison
Is CPHI undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 2/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for CPHI?
Other financial metrics that can be useful for relative valuation.
|What is CPHI's n/a Ratio?|
Price to Sales Ratio vs Peers
How does CPHI's PS Ratio compare to its peers?
|CPHI PS Ratio vs Peers|
|Company||PS||Estimated Growth||Market Cap|
SNOA Sonoma Pharmaceuticals
EMMA Emmaus Life Sciences
NBY NovaBay Pharmaceuticals
GPFT Grapefruit USA
CPHI China Pharma Holdings
Price-To-Sales vs Peers: CPHI is good value based on its Price-To-Sales Ratio (0.9x) compared to the peer average (7.2x).
Price to Earnings Ratio vs Industry
How does CPHI's PE Ratio compare vs other companies in the US Pharmaceuticals Industry?
Price-To-Sales vs Industry: CPHI is good value based on its Price-To-Sales Ratio (0.9x) compared to the US Pharmaceuticals industry average (2.9x)
Price to Sales Ratio vs Fair Ratio
What is CPHI's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PS Ratio||0.9x|
|Fair PS Ratio||n/a|
Price-To-Sales vs Fair Ratio: Insufficient data to calculate CPHI's Price-To-Sales Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of CPHI when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate CPHI's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate CPHI's fair value for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
How is China Pharma Holdings forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as China Pharma Holdings has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Discover growth companies
- Take a look at our analysis of CPHI’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
How has China Pharma Holdings performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: CPHI is currently unprofitable.
Growing Profit Margin: CPHI is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: CPHI is unprofitable, but has reduced losses over the past 5 years at a rate of 20.6% per year.
Accelerating Growth: Unable to compare CPHI's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CPHI is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (5%).
Return on Equity
High ROE: CPHI has a negative Return on Equity (-92.56%), as it is currently unprofitable.
Discover strong past performing companies
How is China Pharma Holdings's financial position?
Financial Health Score1/6
Financial Health Score 1/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: CPHI's short term assets ($6.3M) do not cover its short term liabilities ($8.4M).
Long Term Liabilities: CPHI's short term assets ($6.3M) exceed its long term liabilities ($5.5M).
Debt to Equity History and Analysis
Debt Level: CPHI's net debt to equity ratio (204.7%) is considered high.
Reducing Debt: CPHI's debt to equity ratio has increased from 24.6% to 260.5% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: CPHI has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: CPHI has less than a year of cash runway if free cash flow continues to reduce at historical rates of 48.2% each year
Discover healthy companies
What is China Pharma Holdings's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Dividend Yield vs Market
|China Pharma Holdings Dividend Yield vs Market|
|Company (China Pharma Holdings)||n/a|
|Market Bottom 25% (US)||1.6%|
|Market Top 25% (US)||4.6%|
|Industry Average (Pharmaceuticals)||2.6%|
|Analyst forecast in 3 Years (China Pharma Holdings)||n/a|
Notable Dividend: Unable to evaluate CPHI's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate CPHI's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if CPHI's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CPHI's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as CPHI has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Zhilin Li (69 yo)
Ms. Zhilin Li has been the Chief Executive Officer and President of China Pharma Holdings, Inc. since October 20, 2005 and serves as its Interim Chief Financial Officer. Ms. Li is Founder of Helpson Bio-ph...
CEO Compensation Analysis
|Zhilin Li's Compensation vs China Pharma Holdings Earnings|
|Date||Total Comp.||Salary||Company Earnings|
|Jun 30 2022||n/a||n/a|
|Mar 31 2022||n/a||n/a|
|Dec 31 2021||US$242k||US$226k|
|Sep 30 2021||n/a||n/a|
|Jun 30 2021||n/a||n/a|
|Mar 31 2021||n/a||n/a|
|Dec 31 2020||US$242k||US$226k|
|Sep 30 2020||n/a||n/a|
|Jun 30 2020||n/a||n/a|
|Mar 31 2020||n/a||n/a|
|Dec 31 2019||US$242k||US$226k|
|Sep 30 2019||n/a||n/a|
|Jun 30 2019||n/a||n/a|
|Mar 31 2019||n/a||n/a|
|Dec 31 2018||US$242k||US$226k|
|Sep 30 2018||n/a||n/a|
|Jun 30 2018||n/a||n/a|
|Mar 31 2018||n/a||n/a|
|Dec 31 2017||US$242k||US$226k|
|Sep 30 2017||n/a||n/a|
|Jun 30 2017||n/a||n/a|
|Mar 31 2017||n/a||n/a|
|Dec 31 2016||US$242k||US$226k|
|Sep 30 2016||n/a||n/a|
|Jun 30 2016||n/a||n/a|
|Mar 31 2016||n/a||n/a|
|Dec 31 2015||US$242k||US$226k|
Compensation vs Market: Zhilin's total compensation ($USD241.60K) is below average for companies of similar size in the US market ($USD781.86K).
Compensation vs Earnings: Zhilin's compensation has been consistent with company performance over the past year.
Experienced Board: CPHI's board of directors are seasoned and experienced ( 14.7 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
|Owner Type||Number of Shares||Ownership Percentage|
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 15.8%.
|Ownership||Name||Shares||Current Value||Change %||Portfolio %|
China Pharma Holdings, Inc.'s employee growth, exchange listings and data sources
- Name: China Pharma Holdings, Inc.
- Ticker: CPHI
- Exchange: NYSEAM
- Founded: 1993
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$7.063m
- Shares outstanding: 50.45m
- Website: https://www.chinapharmaholdings.com
Number of Employees
- China Pharma Holdings, Inc.
- No. 17, Jinpan Road
- Second Floor
- Hainan Province
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|CPHI||NYSEAM (NYSE MKT LLC)||Yes||Common Stock||US||USD||Apr 2002|
|XQJ||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Apr 2002|
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/10/03 00:00|
|End of Day Share Price||2022/10/03 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.